85P Safety and efficacy of atezolizumab (Atezo) + bevacizumab (Bev) in Japanese patients (pts) with unresectable hepatocellular carcinoma (uHCC): A prospective, multicenter, observational study (ELIXIR) - A preliminary analysis

M. Ikeda,N. Kato, T. Kagawa, T. Yamashita, M. Moriguchi,S. Nakamura, K. Sawada, H. Iijima, T. Kamoshida, K. Nakao, K. Ohkawa, R. Sugimoto, T. Takehara, M. Harada,Y. Yamamoto, T. Ito, M. Kudo, N. Kokudo,K. Yamamoto, J. Furuse

Annals of Oncology（2022）

引用 0|浏览8